Zokinvy (lonafarnib capsules – Eiger Biopharmaceuticals) — Cigna

Initial criteria

• Patient age ≥ 12 months
• Patient has body surface area ≥ 0.39 m2
• Genetic testing demonstrates a confirmed pathogenic variant in the LMNA gene consistent with Hutchinson-Gilford Progeria Syndrome
• Medication is prescribed by or in consultation with a geneticist or pediatric cardiologist

Approval duration

1 year